• Over of all melanomas have activating

  2022-03-10

  

  Over 50% of all melanomas have activating BRAF mutations [29] and inhibition of the Ras/Raf/MEK/ERK signaling pathways is one of the most promising treatments for malignant melanoma [30]. However, studies using BRAF inhibitors have identified various feedback mechanisms to activate BRAF pathway in m

• transferases Introduction of a chloropyridine group onto the

  2022-03-10

  

  Introduction of a chloropyridine group onto the fluoro derivative (→) leads to a similarly potent compound that exhibits a lower /, and as was observed with (), was rapidly cleared. However, the high clearance of () did not prevent the increase in the concentrations of FAAs even as its plasma levels

• The Jumonji JmjC domain containing KDM

  2022-03-10

  

  The Jumonji (JmjC) domain-containing KDM family members can be clustered into seven subfamilies (KDM2 – KDM8). The KDM2 cluster catalyzes H3K36me2/me1 demethylation; in addition, KDM2B/JHDM1B/FBXL10 has been suggested to catalyze demethylation of H3K4me3 [3]. Cell culture studies support that KDM2 p

• There have been a few studies investigating the effects of

  2022-03-10

  

  There have been a few studies investigating the effects of histamine on mast cells but the majority of these has been on rodent and cultured mast cells (Hofstra et al., 2003, Lippert et al., 2004, Jemima et al., 2014). How representative these systems are of primary human cells is a moot point since

• In conclusion studies of the

  2022-03-10

  

  In conclusion, studies of the regulation of the HO-1/BVR/CO pathway by selective pharmacological approaches may lead to the discovery of novel compounds for the treatment of diverse diseases. Recent results validate the use of advances in targeting HO-1 in various vascular diseases. However, there a

• Based on pharmacophore modeling a good HDAC inhibitor has at

  2022-03-10

  

  Based on pharmacophore modeling, a good HDAC inhibitor has at least three sides/regions: the attachment side of the Zn2+ cofactor/HDAC active site (Zn2+ binding group/ZBG), hydrophobic cap (CAP) and linker containing connecting unit (CU) with electronegative groups (Mohan et al., 2011, Rossi et al.,

• In summary P P macrocyclization proved to

  2022-03-10

  

  In summary, P2-P4 macrocyclization proved to be an effective strategy to drive activity in this series of HCV NS3 protease inhibitors while microsomal stability was enhanced by the introduction of steric bulk along the tether. This modification augmented the previously-described tactic of improving

• In this new therapeutic era nucleic

  2022-03-10

  

  In this new therapeutic era, nucleic APO866 receptor amplification tests (NAATs) remain critically useful. NAATs are recommended to detect HCV RNA in blood following initial serologic diagnosis of HCV infection, to distinguish between spontaneous resolution and progression to chronic infection [7].

• trilithium Acknowledgements We appreciated the contributions

  2022-03-10

  

  Acknowledgements We appreciated the contributions of Ana Carolina Galha, Selma XSL Pinheiro and Islene Azevedo for technical assistances. In addition, we wish to thank Adilson José de Almeida (in memoriam), Moyra M Portilho, Vanessa A Marques and Letícia P Scalioni, for data analysis during the set

• Following our initial observation of an unexpected increase

  2022-03-10

  

  Following our initial observation of an unexpected increase in the maximal rates of cGMP formation by NO-stimulated sGC in the presence of cytosolic PCA preparations [15], we attempted to purify, identify and characterize the responsible protein(s). The purification protocol described in the present

• Pharmacologic approaches of inhibiting GSNOR activity have

  2022-03-10

  

  Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications

• A number of in vivo studies have investigated the

  2022-03-10

  

  A number of in vivo studies have investigated the antitumor activity of distinct GSK-3 inhibitors in a variety of cancer cell line-derived tumor xenograft models [14], [21], [22], [24], [33], [39], [40]. These studies utilized toolkit GSK-3 inhibitors as monotherapies. Although inhibition of tumor g

• Thus synthesized thienopyrimidine derivatives were evaluated

  2022-03-09

  

  Thus synthesized thienopyrimidine derivatives were evaluated in vitro for GPR119 agonistic activity, and the results are summarized in , , . First, we fixed the 4-methylsulfonylphenyl substituent at the R position on the thienopyrimidine ring, and derivatized at the R position. As shown in , and s

• GPR is a member of

  2022-03-09

  

  GPR119 is a member of the G protein-coupled receptor family, and is highly expressed in pancreatic β-cells and intestinal endocrine cells. It has been proposed that GPR119 agonists modulate glucose homeostasis by indirectly stimulating glucose-dependent insulin release through enhancing pancreatic c

• br Experimental procedure br Acknowledgments

  2022-03-09

  

  Experimental procedure Acknowledgments This research was supported by funds provided by NIH/NIAAA grant P01 AA020683 and the Waggoner Center for Alcohol and Addiction Research. Introduction Acute mesenteric ischemia (AMI) is still associated with a high mortality rate, and currently, an ea

14651 records 421/977 page Previous Next First page 上5页 421422423424425 下5页 Last page